Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronidazole followed by probiotic versus metronidazole followed by placebo for functional flatulence
IRCT20230912059417N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of metronidazole and Placebo-COD Research Private Ltd in flatulence (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Flatulence and Quality of life. Started Jan 2024; status: completed.
02
Drugs
metronidazolePlacebo-COD Research Private Ltd
03
Conditions
flatulence
Beyond the preview
Go deeper on IRCT20230912059417N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230912059417N1.